A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9–15) PROMISEmeso trial - Popat, S; Curioni-Fontecedro, A; Dafni, U (Ann Oncol, 2020)
et al.